Komori
Mani (7730) · FactInterim Research and Development Expenses Updated

Continued Investment in Research and Development

First written in FY2016-Q3. . Latest entry: FY2026-H1.

36entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2016-Q3 – FY2026-H12016: 220162017: 420172018: 420182019: 420192020: 420202021: 420212022: 320222023: 420232024: 420242025: 220252026: 1
Same theme, other companies
Continuation of Company-wide R&D Activities and Resource InvestmentA theme 204 companies write about · 0 as a headwind · 217 as a tailwind

90 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 186 companies compared. The sentences above are computed from all 186.Comparing 200 of the theme's 219 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1Interim Research and Development Expenses UpdatedAnnual report

    「Group-wide R&D expenses for the interim consolidated period were ¥1,212 million.」

    Updated R&D expenses to ¥1,212 million for FY2026-H1.
  2. FY2025Full-Year R&D Expense UpdateAnnual report

    「Total R&D expenses for the fiscal year were ¥2,623 million, equivalent to 8.8% of net sales.」

    Updated full-year R&D expenses to ¥2,623 million, equivalent to 8.8% of net sales.
  3. FY2025-H1Interim Research and Development Expenses UpdatedAnnual report

    「Group-wide R&D expenses for the interim consolidated period were ¥1,311 million.」

    Disclosed R&D expenses of ¥1,311 million for FY2025-H1.
  4. FY2024Full-Year R&D Expense UpdateAnnual report

    「Total R&D expenses for the fiscal year were ¥2,396 million, equivalent to 8.4% of net sales.」

    Disclosed full-year R&D expenses of ¥2,396 million, equivalent to 8.4% of net sales, up from ¥2,187 million in the previous fiscal year.
  5. FY2024-Q3Update to R&D expenses for the first 3 quartersAnnual report

    「Group-wide R&D expenses for the cumulative third quarter were ¥1,813 million.」

    Disclosed cumulative R&D expenses of ¥1,813 million for FY2024-Q3.
  6. FY2024-Q2Second-quarter research and development expenses updatedAnnual report

    「Group-wide R&D expenses for the cumulative second quarter were ¥1,125 million.」

    Disclosed cumulative R&D expenses of ¥1,125 million for FY2024-Q2.
  7. FY2024-Q1Update to first-quarter R&D expensesAnnual report

    「Group-wide R&D expenses for the cumulative first quarter were ¥547 million.」

    Disclosed R&D expenses of ¥547 million for FY2024-Q1.
  8. FY2023Full-Year R&D Expense UpdateAnnual report

    「Total R&D expenses for the fiscal year were ¥2,187 million, equivalent to 8.9% of net sales.」

    Disclosed full-year R&D expenses of ¥2,187 million, equivalent to 8.9% of net sales.
  9. FY2023-Q3Update to R&D expenses for the first 3 quartersAnnual report

    「Group-wide R&D expenses for the cumulative third quarter were ¥1,574 million.」

    Disclosed cumulative R&D expenses of ¥1,574 million for FY2023-Q3.
  10. FY2023-Q2Second-quarter research and development expenses updatedAnnual report

    「Group-wide R&D expenses for the cumulative second quarter were ¥1,002 million.」

    Disclosed cumulative R&D expenses of ¥1,002 million for the second quarter.
  11. FY2023-Q1Update to first-quarter R&D expensesAnnual report

    「Group-wide R&D expenses for the cumulative first quarter were ¥508 million.」

    Disclosed R&D expenses of ¥508 million for FY2023-Q1.
  12. FY2022-Q3Update to R&D expenses for the first 3 quartersAnnual report

    「Group-wide R&D expenses for the cumulative third quarter were ¥1,082 million.」

    Disclosed cumulative R&D expenses of ¥1,082 million for FY2022-Q3.
  13. FY2022-Q2Second-quarter research and development expenses updatedAnnual report

    「The Group's total research and development expenses during the six-month period of the current consolidated fiscal year were ¥727 million.」

    Disclosed R&D expenses of ¥727 million for the cumulative second quarter.
  14. FY2022-Q1Update to first-quarter R&D expensesAnnual report

    「The Group's total research and development expenses during the three-month period of the current consolidated fiscal year were ¥334 million.」

    Disclosed R&D expenses of ¥334 million for FY2022-Q1.
  15. FY2021Full-Year R&D Expense UpdateAnnual report

    「Total research and development expenses for the current consolidated fiscal year were ¥1,498 million, representing 8.7% of net sales.」

    The Company disclosed full-year research and development expenses of ¥1,498 million, representing 8.7% of net sales. Both the amount and the ratio declined from ¥1,589 million and 10.5%, respectively, in the previous fiscal year.
  16. FY2021-Q3Update to R&D expenses for the first 3 quartersAnnual report

    「The Group's total research and development expenses during the nine-month period of the current consolidated fiscal year were ¥1,084 million.」

    The Company disclosed research and development expenses of ¥1,084 million for FY2021-Q3.
  17. FY2021-Q2Second-quarter research and development expenses updatedAnnual report

    「The Group's total research and development expenses during the six-month period of the current consolidated fiscal year were ¥727 million.」

    The Company disclosed research and development expenses of ¥727 million for FY2021-Q2, down from ¥820 million in the same period of the previous fiscal year.
  18. FY2021-Q1Update to first-quarter R&D expensesAnnual report

    「The Group's total research and development expenses during the three-month period of the current consolidated fiscal year were ¥355 million.」

    The Company disclosed research and development expenses of ¥355 million for FY2021-Q1.
  19. FY2020Full-Year R&D Expense UpdateAnnual report

    「Total research and development expenses for the current consolidated fiscal year were ¥1,589 million, representing 10.5% of net sales.」

    The Company disclosed full-year research and development expenses of ¥1,589 million, representing 10.5% of net sales.
  20. FY2020-Q3Update to R&D expenses for the first 3 quartersAnnual report

    「The Group's total research and development expenses during the nine-month period of the current consolidated fiscal year were ¥1,183 million.」

    The Company disclosed research and development expenses of ¥1,183 million for the nine-month period of the 61st fiscal year.
  21. FY2020-Q2Second-quarter research and development expenses updatedAnnual report

    「The Group's total research and development expenses during the six-month period of the current consolidated fiscal year were ¥820 million.」

    The Company disclosed research and development expenses of ¥820 million for FY2020-Q2.
  22. FY2020-Q1Update to first-quarter R&D expensesAnnual report

    「The Group's total research and development expenses during the three-month period of the current consolidated fiscal year were ¥409 million.」

    The Company disclosed research and development expenses of ¥409 million for FY2020-Q1.
  23. FY2019Full-Year R&D Expense UpdateAnnual report

    「Total research and development expenses for the current consolidated fiscal year were ¥1,693 million, representing 9.2% of net sales.」

    The Company disclosed full-year research and development expenses of ¥1,693 million, representing 9.2% of net sales, up from ¥1,614 million and 8.0%, respectively, in the previous fiscal year.
  24. FY2019-Q3Third-quarter results disclosedAnnual report

    「The Group's total research and development expenditure during the nine-month period of the current consolidated fiscal year was ¥1,287 million.」

    The Company disclosed research and development expenditure of ¥1,287 million for the nine-month period of the 60th fiscal year.
  25. FY2019-Q2Second-quarter results disclosedAnnual report

    「The Group's total research and development expenditure during the six-month period of the current consolidated fiscal year was ¥817 million.」

    The Company disclosed research and development expenditure of ¥817 million for the six-month period of the 60th fiscal year.
  26. FY2019-Q1First-quarter results disclosedAnnual report

    「The Group's total research and development expenditure during the three-month period of the current consolidated fiscal year was ¥451 million.」

    The Company disclosed research and development expenditure of ¥451 million for FY2019-Q1.
  27. FY2018Full-year results disclosedAnnual report

    「Research and development expenses for the current consolidated fiscal year were ¥1,614 million, representing 8.0% of net sales.」

    The Company disclosed full-year research and development expenses of ¥1,614 million and a ratio to net sales of 8.0%.
  28. FY2018-Q3Third-quarter results disclosedAnnual report

    「The Group's total research and development expenditure during the nine-month period of the current consolidated fiscal year was ¥1,184 million.」

    The Company disclosed research and development expenditure of ¥1,184 million for the nine-month period of the 59th fiscal year.
  29. FY2018-Q2Second-quarter results disclosedAnnual report

    「The Group's total research and development expenditure during the six-month period of the current consolidated fiscal year was ¥730 million.」

    The Company disclosed research and development expenditure of ¥730 million for the six-month period of the 59th fiscal year.
  30. FY2018-Q1First-quarter results disclosedAnnual report

    「The Group's total research and development expenditure during the three-month period of the current consolidated fiscal year was ¥354 million.」

    The Company disclosed research and development expenditure of ¥354 million for the first quarter of the 59th fiscal year.
  31. FY2017Full-year results disclosedAnnual report

    「Research and development expenses for the current consolidated fiscal year were ¥1,221 million, representing 7.1% of net sales.」

    The Company disclosed full-year research and development expenses of ¥1,221 million, representing 7.1% of net sales.
  32. FY2017-Q3Third-quarter results disclosedAnnual report

    「The Group's total research and development expenditure during the nine-month period of the current consolidated fiscal year was ¥861 million.」

    The Company disclosed research and development expenditure of ¥861 million for the nine-month period of the current consolidated fiscal year.
  33. FY2017-Q2Second-quarter results disclosedAnnual report

    「The Group's total research and development expenditure during the six-month period of the current consolidated fiscal year was ¥563 million.」

    The Company disclosed research and development expenditure of ¥563 million for the six-month period of the current consolidated fiscal year.
  34. FY2017-Q1First-quarter results disclosedAnnual report

    「The Group's total research and development expenditure during the three-month period of the current consolidated fiscal year was ¥279 million.」

    Following full-year research and development expenses of ¥1,278 million, the Company disclosed research and development expenditure of ¥279 million for the first quarter.
  35. FY2016Full-year results disclosedAnnual report

    「Research and development expenses for the current consolidated fiscal year were ¥1,278 million, representing 7.7% of net sales.」

    The Company updated the disclosure from cumulative quarterly research and development expenses to the full-year amount and percentage of net sales, and also disclosed the specific scope of its research and development activities.
  36. FY2016-Q3First statedAnnual report

    「The Group's total research and development expenditure during the nine-month period of the current consolidated fiscal year was ¥979 million.」

    The Company disclosed research and development expenditure of ¥979 million for the nine-month period of the current fiscal year.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Mani's next results are scheduled for 2026-10-15. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Continued Investment in Research and Development | MANI,INC. (7730) | Komori